{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:39:17Z","timestamp":1791599957251,"version":"4.3.4"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T00:00:00Z","timestamp":1581033600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T00:00:00Z","timestamp":1581033600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["80-84800-98-41015"],"award-info":[{"award-number":["80-84800-98-41015"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Antipsychotic medication is effective for symptomatic treatment in schizophrenia-spectrum disorders. After symptom remission, continuation of antipsychotic treatment is associated with lower relapse rates and lower symptom severity compared to dose reduction\/discontinuation. Therefore, most guidelines recommend continuation of treatment with antipsychotic medication for at least 1 year. Recently, however, these guidelines have been questioned as one study has shown that more patients achieved long-term functional remission in an early discontinuation condition\u2014a finding that was not replicated in another recently published long-term study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods\/design<\/jats:title>\n                <jats:p>The HAMLETT (Handling Antipsychotic Medication Long-term Evaluation of Targeted Treatment) study is a multicenter pragmatic single-blind randomized controlled trial in two parallel conditions (1:1) investigating the effects of continuation versus dose-reduction\/discontinuation of antipsychotic medication after remission of a first episode of psychosis (FEP) on personal and social functioning, psychotic symptom severity, and health-related quality of life. In total 512 participants will be included, aged between 16 and 60\u2009years, in symptomatic remission from a FEP for 3\u20136\u2009months, and for whom psychosis was not associated with severe or life-threatening self-harm or violence. Recruitment will take place at 24 Dutch sites. Patients are randomized (1:1) to: continuation of antipsychotic medication until at least 1\u2009year after remission (original dose allowing a maximum reduction of 25%, or another antipsychotic drug in similar dose range); or gradual dose reduction till eventual discontinuation of antipsychotics according to a tapering schedule. If signs of relapse occur in this arm, medication dose can be increased again. Measurements are conducted at baseline, at 3, and 6 months post-baseline, and yearly during a follow-up period of 4\u2009years.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>The HAMLETT study will offer evidence to guide patients and clinicians regarding questions concerning optimal treatment duration and when to taper off medication after remission of a FEP. Moreover, it may provide patient characteristics associated with safe dose reduction with a minimal risk of relapse.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial status<\/jats:title>\n                <jats:p>Protocol version 1.3, October 2018. The study is active and currently recruiting patients (since September 2017), with the first 200 participants by the end of 2019. We anticipate completing recruitment in 2022 and final assessments (including follow-up 3.5 years after phase one) in 2026.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>European Clinical Trials Database, EudraCT number <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-002406-12\/NL\">2017-002406-12<\/jats:ext-link>. Registered 7 June 2017.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-019-3822-5","type":"journal-article","created":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T10:02:47Z","timestamp":1581069767000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["To continue or not to continue? Antipsychotic medication maintenance versus dose-reduction\/discontinuation in first episode psychosis: HAMLETT, a pragmatic multicenter single-blind randomized controlled trial"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6448-2799","authenticated-orcid":false,"given":"Marieke J. H.","family":"Begemann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilse A.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Veling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiral S.","family":"Gangadin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris N. W.","family":"Geraets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erna","family":"van \u2018t Hag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne J.","family":"M\u00fcller-Kuperus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla P.","family":"Oomen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alban E.","family":"Voppel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"van der Gaag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn J.","family":"Kikkert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Van Os","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Filip E.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikus H.","family":"Knegtering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sybren","family":"Wiersma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyken H.","family":"Stouten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harm J.","family":"Gijsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lex","family":"Wunderink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton B. P.","family":"Staring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selene R. T.","family":"Veerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrita G. S.","family":"Mahabir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Kurkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerdina H. M.","family":"Pijnenborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie D.","family":"Veen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Machteld","family":"Marcelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen P.","family":"Grootens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Faber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico J.","family":"van Beveren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agaath","family":"Been","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Truus","family":"van den Brink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Bak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Therese A. M. J.","family":"van Amelsvoort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ruissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Blanke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Groen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieuwe","family":"de Haan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris E. C.","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,7]]},"reference":[{"issue":"1\u20133","key":"3822_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.schres.2010.05.025","volume":"122","author":"R Tandon","year":"2010","unstructured":"Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia,\u201cJust the Facts\u201d 5. Treatment and prevention past, present, and future. Schizophr Res. 2010;122(1\u20133):1\u201323.","journal-title":"Schizophr Res"},{"key":"3822_CR2","volume-title":"Psychosis and schizophrenia in adults: treatment and management. National clinical guideline 178","author":"National Institute for Clinical Excellence","year":"2014","unstructured":"National Institute for Clinical Excellence. Psychosis and schizophrenia in adults: treatment and management. National clinical guideline 178. London: National Institute for Clinical Excellence; 2014. Retrieved at: https:\/\/www.nice.org.uk\/guidance\/cg178"},{"key":"3822_CR3","volume-title":"Australian clinical guidelines for early psychosis. A brief summary for practitioners","author":"Early Psychosis Guidelines Writing Group","year":"2010","unstructured":"Early Psychosis Guidelines Writing Group. Australian clinical guidelines for early psychosis. A brief summary for practitioners. 2nd ed. Melbourne: Orygen Youth Health; 2010.","edition":"2"},{"key":"3822_CR4","unstructured":"Veling W, Boonstra N, van Doorn H, van der Gaag M, Gijsman M, de Haan L, et al. Zorgstandaard psychose, module Vroege Psychose. Utrecht: Netwerk Kwaliteitsontwikkeling GGZ; 2017."},{"issue":"1","key":"3822_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/WNF.0000000000000117","volume":"39","author":"E Longden","year":"2016","unstructured":"Longden E, Read J. Assessing and reporting the adverse effects of antipsychotic medication: a systematic review of clinical studies, and prospective, retrospective, and cross-sectional research. Clin Neuropharmacol. 2016;39(1):29\u201339.","journal-title":"Clin Neuropharmacol"},{"key":"3822_CR6","doi-asserted-by":"publisher","unstructured":"Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Davis JM. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2012;(5):CD008016. https:\/\/doi.org\/10.1002\/14651858.CD008016.pub2.","DOI":"10.1002\/14651858.CD008016.pub2"},{"key":"3822_CR7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2147\/NDT.S96392","volume":"12","author":"C Karson","year":"2016","unstructured":"Karson C, Duffy RA, Eramo A, Nylander AG, Offord SJ. Long-term outcomes of antipsychotic treatment in patients with first-episode schizophrenia: a systematic review. Neuropsychiatr Dis Treat. 2016;12:57.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"5","key":"3822_CR8","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s40263-016-0331-x","volume":"30","author":"M Alvarez-Jimenez","year":"2016","unstructured":"Alvarez-Jimenez M, O\u2019Donoghue B, Thompson A, Gleeson JF, Bendall S, Gonzalez-Blanch C, Killackey E, Wunderink L, McGorry PD. Beyond clinical remission in first episode psychosis: thoughts on antipsychotic maintenance vs. guided discontinuation in the functional recovery era. CNS Drugs. 2016;30(5):357\u201368.","journal-title":"CNS Drugs"},{"issue":"4","key":"3822_CR9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1192\/bjo.2018.17","volume":"4","author":"A Thompson","year":"2018","unstructured":"Thompson A, Winsper C, Marwaha S, Haynes J, Alvarez-Jimenez M, Hetrick S, Realpe A, Vail L, Dawson S, Sullivan SA. Maintenance antipsychotic treatment versus discontinuation strategies following remission from first episode psychosis: systematic review. BJPsych Open. 2018;4(4):215\u201325.","journal-title":"BJPsych Open"},{"issue":"1\u20132","key":"3822_CR10","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0920-9964(01)00182-7","volume":"53","author":"W Gaebel","year":"2002","unstructured":"Gaebel W, J\u00e4nner M, Frommann N, Pietzcker A, K\u00f6pcke W, Linden M, M\u00fcller P, M\u00fcller-Spahn F, Tegeler J. First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies. Schizophrenia Res. 2002;53(1\u20132):145\u201359.","journal-title":"Schizophrenia Res"},{"issue":"9","key":"3822_CR11","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1001\/jamapsychiatry.2013.19","volume":"70","author":"L Wunderink","year":"2013","unstructured":"Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction\/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry. 2013;70(9):913\u201320.","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"3822_CR12","doi-asserted-by":"publisher","first-page":"654","DOI":"10.4088\/JCP.v68n0502","volume":"68","author":"L Wunderink","year":"2007","unstructured":"Wunderink L, Nienhuis FJ, Sytema S, Slooff CJ, Knegtering R, Wiersma D. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J Clin Psychiatry. 2007;68(5):654\u201361.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"3822_CR13","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/S2215-0366(18)30090-7","volume":"5","author":"CL Hui","year":"2018","unstructured":"Hui CL, Honer WG, Lee EH, Chang WC, Chan SK, Chen ES, Pang EP, Lui SS, Chung DW, Yeung WS, Ng RM. Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial. Lancet Psychiatry. 2018;5(5):432\u201342.","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"3822_CR14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.4088\/JCP.09m05459yel","volume":"72","author":"W Gaebel","year":"2011","unstructured":"Gaebel W, Riesbeck M, W\u00f6lwer W, Klimke A, Eickhoff M, Lemke M, Heuser I, Maier W, Huff W, Schmitt A, Sauer H. Relapse prevention in first-episode schizophrenia-- maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry. 2011;72(2):205\u201318.","journal-title":"J Clin Psychiatry"},{"issue":"8","key":"3822_CR15","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1176\/appi.ajp.2018.17091001","volume":"175","author":"Jari Tiihonen","year":"2018","unstructured":"Tiihonen J, Tanskanen A, Taipale H. 20-year nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode schizophrenia. Am J Psychiatry. 2018;175(8):765-773.","journal-title":"American Journal of Psychiatry"},{"issue":"8","key":"3822_CR16","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1001\/archgenpsychiatry.2012.169","volume":"69","author":"OD Howes","year":"2012","unstructured":"Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A, Kapur S. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry. 2012;69(8):776\u201386.","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"3822_CR17","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1176\/appi.ajp.157.6.1019","volume":"157","author":"L de Haan","year":"2000","unstructured":"de Haan L, Lavalaye J, Linszen D, Dingemans PM, Booij J. Subjective experience and striatal dopamine D2 receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. Am J Psychiatr. 2000;157(6):1019\u201320.","journal-title":"Am J Psychiatr"},{"issue":"2","key":"3822_CR18","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1176\/appi.ajp.160.2.303","volume":"160","author":"L de Haan","year":"2003","unstructured":"de Haan L, van Bruggen M, Lavalaye J, Booij J, Dingemans PM, Linszen D. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. Am J Psychiatr. 2003;160(2):303\u20139.","journal-title":"Am J Psychiatr"},{"issue":"4","key":"3822_CR19","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1176\/ajp.2007.164.4.630","volume":"164","author":"R Mizrahi","year":"2007","unstructured":"Mizrahi R, Rusjan P, Agid O, Graff A, Mamo DC, Zipursky RB, Kapur S. Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2receptors: a PET study in schizophrenia. Am J Psychiatry. 2007;164(4):630\u20137.","journal-title":"Am J Psychiatry"},{"issue":"5","key":"3822_CR20","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/S0893-133X(01)00263-9","volume":"25","author":"L Voruganti","year":"2001","unstructured":"Voruganti L, Slomka P, Zabel P, Costa G, So A, Mattar A, Awad AG. Subjective effects of AMPT-induced dopamine depletion in schizophrenia: correlation between dysphoric responses and striatal D 2 binding ratios on SPECT imaging. Neuropsychopharmacology. 2001;25(5):642.","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"3822_CR21","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3758\/s13415-014-0261-3","volume":"14","author":"C Insel","year":"2014","unstructured":"Insel C, Reinen J, Weber J, Wager TD, Jarskog LF, Shohamy D, Smith EE. Antipsychotic dose modulates behavioral and neural responses to feedback during reinforcement learning in schizophrenia. Cogn Affect Behav Neurosci. 2014;14(1):189\u2013201.","journal-title":"Cogn Affect Behav Neurosci"},{"issue":"6","key":"3822_CR22","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/01.jcp.0000185423.15891.02","volume":"25","author":"C Barbui","year":"2005","unstructured":"Barbui C, Nos\u00e8 M, Bindman J, Schene A, Becker T, Mazzi MA, Kikkert M, Camara J, Born A, Tansella M. Sex differences in the subjective tolerability of antipsychotic drugs. J Clin Psychopharmacol. 2005;25(6):521\u20136.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"3822_CR23","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1124\/pr.115.010512","volume":"67","author":"AF Arnsten","year":"2015","unstructured":"Arnsten AF, Wang M, Paspalas CD. Dopamine\u2019s actions in primate prefrontal cortex: challenges for treating cognitive disorders. Pharmacol Rev. 2015;67(3):681\u201396.","journal-title":"Pharmacol Rev"},{"issue":"12","key":"3822_CR24","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1038\/npp.2012.129","volume":"37","author":"SB Ostlund","year":"2012","unstructured":"Ostlund SB, Kosheleff AR, Maidment NT. Relative response cost determines the sensitivity of instrumental reward seeking to dopamine receptor blockade. Neuropsychopharmacology. 2012;37(12):2653.","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"3822_CR25","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1192\/bjp.bp.106.029009","volume":"192","author":"A Zs\u00f6ke","year":"2008","unstructured":"Zs\u00f6ke A, Trandafir A, Dupont ME, Meary A, Sch\u00fcrhoff F, Leboyer M. Longitudinal studies of cognition in schizophrenia: meta-analysis. Br J Psychiatry. 2008;192(4):248\u201357.","journal-title":"Br J Psychiatry"},{"issue":"4","key":"3822_CR26","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.eurpsy.2011.02.003","volume":"27","author":"G Faber","year":"2012","unstructured":"Faber G, Smid HG, Van Gool AR, Wiersma D, Van Den Bosch RJ. The effects of guided discontinuation of antipsychotics on neurocognition in first onset psychosis. Eur Psychiatry. 2012;27(4):275\u201380.","journal-title":"Eur Psychiatry"},{"issue":"5","key":"3822_CR27","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1017\/S0033291718001393","volume":"49","author":"Taro Kishi","year":"2018","unstructured":"Kishi T, Ikuta T, Matsui Y, Inada K, Matsuda Y, Mishima K, Iwata N. Effect of discontinuation v. maintenance of antipsychotic medication on relapse rates in patients with remitted\/stable first-episode psychosis: a meta-analysis. Psychol Med. 2019;49(5):772-779.","journal-title":"Psychological Medicine"},{"issue":"3","key":"3822_CR28","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","volume":"158","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, Altman DG, Laupacis A, G\u00f8tzsche PC, Krle\u017ea-Jeri\u0107 K, Hr\u00f3bjartsson A, Mann H, Dickersin K, Berlin JA, Dor\u00e9 CJ. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200\u20137.","journal-title":"Ann Intern Med"},{"key":"3822_CR29","volume-title":"Multidisciplinaire richtlijn schizofrenie","author":"C van Alphen","year":"2012","unstructured":"van Alphen C, Ammeraal M, Blanke C, Boonstra N, Boumans H, Bruggeman R, van Wel T. Multidisciplinaire richtlijn schizofrenie. Utrecht: De Tijdstroom; 2012."},{"issue":"2","key":"3822_CR30","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/MRR.0b013e32830150e6","volume":"31","author":"P Chopra","year":"2008","unstructured":"Chopra P, Herrman H, Kennedy G. Comparison of disability and quality of life measures in patients with long-term psychotic disorders and patients with multiple sclerosis: an application of the WHO Disability Assessment Schedule II and WHO Quality of Life-BREF. Int J Rehabil Res. 2008;31(2):141\u20139.","journal-title":"Int J Rehabil Res"},{"issue":"2-3","key":"3822_CR31","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.schres.2003.09.011","volume":"68","author":"R Keefe","year":"2004","unstructured":"Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The brief assessment of cognition in schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res 2004;68(2\u20133):283\u2013297.","journal-title":"Schizophrenia Research"},{"issue":"5","key":"3822_CR32","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1192\/bjp.166.5.654","volume":"166","author":"SH Jones","year":"1995","unstructured":"Jones SH, Thornicroft G, Coffey M, Dunn G. A brief mental health outcome scale: reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry. 1995;166(5):654\u20139.","journal-title":"Br J Psychiatry"},{"issue":"2","key":"3822_CR33","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261\u201376.","journal-title":"Schizophr Bull"},{"key":"3822_CR34","unstructured":"EuroQol. Standardized instrument for use as a measure of health outcome. Available from: www.euroqol.org. Accessed 4 Dec 2018."},{"issue":"4","key":"3822_CR35","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/j.1600-0447.1993.tb03366.x","volume":"87","author":"J Gerlach","year":"1993","unstructured":"Gerlach J, Korsgaard S, Clemmesen P, Lauersen AM, Magelund G, Noring U, Povlsen UJ, Bech P, Casey DE. The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity. Acta Psychiatr Scand. 1993;87(4):244\u201352.","journal-title":"Acta Psychiatr Scand"},{"issue":"5","key":"3822_CR36","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1192\/bjp.154.5.672","volume":"154","author":"TR Barnes","year":"1989","unstructured":"Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154(5):672\u20136.","journal-title":"Br J Psychiatry"},{"key":"3822_CR37","volume-title":"Construction of a scale to measure consumer recovery","author":"D Giffort","year":"1995","unstructured":"Giffort D, Schmook A, Woody C, Vollendorf C, Gervain M. Construction of a scale to measure consumer recovery. Springfield: Illinois Office of Mental Health; 1995."},{"issue":"8","key":"3822_CR38","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1001\/archpsyc.1992.01820080023004","volume":"49","author":"NC Andreasen","year":"1992","unstructured":"Andreasen NC, Flaum M, Arndt S. The Comprehensive Assessment of Symptoms and History (CASH): an instrument for assessing diagnosis and psychopathology. Arch Gen Psychiatry. 1992;49(8):615\u201323.","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"3822_CR39","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S0145-2134(02)00541-0","volume":"27","author":"DP Bernstein","year":"2003","unstructured":"Bernstein DP, Stein JA, Newcomb MD, Walker E, Pogge D, Ahluvalia T, Stokes J, Handelsman L, Medrano M, Desmond D, Zule W. Development and validation of a brief screening version of the Childhood Trauma Questionnaire. Child Abuse Neglect. 2003;27(2):169\u201390.","journal-title":"Child Abuse Neglect"},{"issue":"5","key":"3822_CR40","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1207\/s15516709cog2505_2","volume":"25","author":"BR Buchsbaum","year":"2001","unstructured":"Buchsbaum BR, Hickok G, Humphries C. Role of left posterior superior temporal gyrus in phonological processing for speech perception and production. Cognitive Sci. 2001;25(5):663\u201378.","journal-title":"Cognitive Sci"},{"issue":"11","key":"3822_CR41","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/j.euroneuro.2015.08.008","volume":"25","author":"FM Bos","year":"2015","unstructured":"Bos FM, Schoevers RA, aan het Rot M. Experience sampling and ecological momentary assessment studies in psychopharmacology: a systematic review. Eur Neuropsychopharmacol. 2015;25(11):1853\u201364.","journal-title":"Eur Neuropsychopharmacol"},{"key":"3822_CR42","unstructured":"BeHapp. Available from: www.behapp.org. Accessed 4 Dec 2018."},{"key":"3822_CR43","unstructured":"Hakkaart-van Roijen L, Straten AV, Tiemens B, Donker MC. Handleiding Trimbos\/iMTA questionnaire for Costs associated with Psychiatric illness (TiC-P). Rotterdam, the Netherlands: Institute of Medical Technology Assessment (iMTA); 2002."},{"issue":"12","key":"3822_CR44","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1037\/0003-066X.48.12.1181","volume":"48","author":"MW Lipsey","year":"1993","unstructured":"Lipsey MW, Wilson DB. The efficacy of psychological, educational, and behavioral treatment: Confirmation from meta-analysis. Am Psychol. 1993;48(12):1181.","journal-title":"Am Psychol"},{"issue":"1","key":"3822_CR45","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1741-7015-8-18","volume":"8","author":"KF Schulz","year":"2010","unstructured":"Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMC Med. 2010;8(1):18.","journal-title":"BMC Med"},{"issue":"2","key":"3822_CR46","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","volume":"16","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E, ISPOR Health Economic Evaluation Publication Guidelines-CHEERS Good Reporting Practices Task Force. Consolidated health economic evaluation reporting standards (CHEERS)\u2014 explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health. 2013;16(2):231\u201350.","journal-title":"Value Health"},{"issue":"3","key":"3822_CR47","doi-asserted-by":"publisher","first-page":"549","DOI":"10.2307\/2530245","volume":"35","author":"Peter C. O'Brien","year":"1979","unstructured":"O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35(3):549-56.","journal-title":"Biometrics"},{"issue":"2\u20133","key":"3822_CR48","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.schres.2011.11.021","volume":"134","author":"H Takeuchi","year":"2012","unstructured":"Takeuchi H, Suzuki T, Uchida H, Watanabe K, Mimura M. Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms. Schizophr Res. 2012;134(2\u20133):219\u201325.","journal-title":"Schizophr Res"},{"issue":"1","key":"3822_CR49","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1186\/s13063-017-2172-4","volume":"18","author":"AE St\u00fcrup","year":"2017","unstructured":"St\u00fcrup AE, Jensen HD, Dolmer S, Birk M, Albert N, Nielsen M, Hjorth\u00f8j C, Eplov L, Ebdrup BH, Mors O, Nordentoft M. TAILOR\u2013tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or persistent delusional disorder in remission of psychotic symptoms: study protocol for a randomized clinical trial. Trials. 2017;18(1):445.","journal-title":"Trials"},{"issue":"6","key":"3822_CR50","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1111\/eip.12769","volume":"13","author":"A Weller","year":"2019","unstructured":"Weller A, Gleeson J, Alvarez-Jimenez M, McGorry P, Nelson B, Allott K, Bendall S, Bartholomeusz C, Koval P, Harrigan S, O'donoghue B. Can antipsychotic dose reduction lead to better functional recovery in first-episode psychosis? A randomized controlled-trial of antipsychotic dose reduction. The reduce trial: Study protocol. Early Interv Psychiatry. 2019;13(6):1345\u201356.","journal-title":"Early Interv Psychiatry"},{"issue":"Supll 1","key":"3822_CR51","doi-asserted-by":"publisher","first-page":"S414","DOI":"10.1093\/schbul\/sby018.1014","volume":"44","author":"CC Liu","year":"2018","unstructured":"Liu CC. S227. A proposed alternative between discontinuation and maintenance of antipsychotics: a guided dose reduction trial for patients with remitted psychosis. Schizophr Bull. 2018;44(Supll 1):S414.","journal-title":"Schizophr Bull"},{"issue":"9","key":"3822_CR52","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1001\/archpsyc.62.9.975","volume":"62","author":"M Marshall","year":"2005","unstructured":"Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry. 2005;62(9):975\u201383.","journal-title":"Arch Gen Psychiatry"},{"key":"3822_CR53","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1034\/j.1601-5215.2003.00038.x","volume":"15","author":"HA Wolters","year":"2003","unstructured":"Wolters HA. Desired and undesired effects of antipsychotic treatment from a patients\u2019 perspective. Acta Neuropsychiatr. 2003;15:274\u20139.","journal-title":"Acta Neuropsychiatr"},{"issue":"1","key":"3822_CR54","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s00213-002-1054-x","volume":"162","author":"L de Haan","year":"2002","unstructured":"de Haan L, Weisfelt M, Dingemans PM, Linszen D, Wouters L. Psychometric properties of the subjective well-being under neuroleptics scale and the subjective deficit syndrome scale. Psychopharmacology. 2002;162(1):24\u20138.","journal-title":"Psychopharmacology"},{"issue":"1","key":"3822_CR55","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.psychres.2003.08.008","volume":"121","author":"JB Ritsher","year":"2003","unstructured":"Ritsher JB, Otilingam PG, Grajales M. Internalized stigma of mental illness: psychometric properties of a new measure. Psychiatry Res. 2003;121(1):31\u201349.","journal-title":"Psychiatry Res"},{"issue":"1","key":"3822_CR56","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.psychres.2005.08.019","volume":"143","author":"T Lecomte","year":"2006","unstructured":"Lecomte T, Corbi\u00e8re M, Laisn\u00e9 F. Investigating self-esteem in individuals with schizophrenia: relevance of the Self-Esteem Rating Scale-Short Form. Psychiatry Res. 2006;143(1):99\u2013108.","journal-title":"Psychiatry Res"},{"issue":"12","key":"3822_CR57","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.brat.2008.08.009","volume":"46","author":"K Berry","year":"2008","unstructured":"Berry K, Barrowclough C, Wearden A. Attachment theory: a framework for understanding symptoms and interpersonal relationships in psychosis. Behav Res Ther. 2008;46(12):1275\u201382.","journal-title":"Behav Res Ther"},{"issue":"3","key":"3822_CR58","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1093\/schbul\/8.3.470","volume":"8","author":"HE Cannon-Spoor","year":"1982","unstructured":"Cannon-Spoor HE, Potkin SG, Wyatt RJ. Measurement of premorbid adjustment in chronic schizophrenia. Schizophr Bull. 1982;8(3):470.","journal-title":"Schizophr Bull"},{"issue":"1","key":"3822_CR59","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1207\/s15327752jpa5201_2","volume":"52","author":"GD Zimet","year":"1988","unstructured":"Zimet GD, Dahlem NW, Zimet SG, Farley GK. The multidimensional scale of perceived social support. J Pers Assess. 1988;52(1):30\u201341.","journal-title":"J Pers Assess"},{"key":"3822_CR60","volume-title":"The Alcohol, Smoking and Substance involvement Screening Test (ASSIST): manual for use in primary care\/prepared by R. Humeniuk [et al]","author":"R Humeniuk","year":"2010","unstructured":"Humeniuk R, Henry-Edwards S, Ali R, Poznyak V, Monteiro MG, World Health Organization. The Alcohol, Smoking and Substance involvement Screening Test (ASSIST): manual for use in primary care\/prepared by R. Humeniuk [et al]. 2010."},{"issue":"6","key":"3822_CR61","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1037\/h0054651","volume":"18","author":"JR Stroop","year":"1935","unstructured":"Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol. 1935;18(6):643.","journal-title":"J Exp Psychol"},{"issue":"2\u20133","key":"3822_CR62","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/0920-9964(95)00096-8","volume":"19","author":"PN van Harten","year":"1996","unstructured":"van Harten PN, Matroos GE, Hoek HW, Kahn RS. The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia The Curacao Extrapyramidal Syndromes Study: I. Schizophr Res. 1996;19(2\u20133):195\u2013203.","journal-title":"Schizophr Res"},{"issue":"4","key":"3822_CR63","first-page":"486","volume":"39","author":"NR Schooler","year":"1982","unstructured":"Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch General Psychiatry. 1982;39(4):486\u20137.","journal-title":"Arch General Psychiatry"},{"key":"3822_CR64","first-page":"167","volume-title":"Drug-induced movement disorders","author":"RE Burke","year":"1992","unstructured":"Burke RE. Neuroleptic-induced tardive dyskinesia variants. In: Lang AE, Weiner WJ, editors. Drug-induced movement disorders. New York: Futura Publishing; 1992. p. 167\u201398."},{"key":"3822_CR65","volume-title":"Drug induced movement disorders","year":"2005","unstructured":"Factor S, Lang A, Weiner W, editors. Drug induced movement disorders. 2nd ed. United Kingdom: Wiley; 2005.","edition":"2"},{"issue":"17","key":"3822_CR66","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","volume":"112","author":"SM Grundy","year":"2005","unstructured":"Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA. Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112(17):2735\u201352.","journal-title":"Circulation"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3822-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-019-3822-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3822-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T05:31:41Z","timestamp":1612762301000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-019-3822-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,7]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["3822"],"URL":"https:\/\/doi.org\/10.1186\/s13063-019-3822-5","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,7]]},"assertion":[{"value":"4 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study has been approved by the Medical Ethics Committee (METC) in Groningen, the Netherlands on August 4, 2017 (METC-number 2017\u2013343). Any substantial changes in the protocol will be reported to the METC in Groningen. Informed consent will be collected by the research team or the dedicated includers. Participants will have time to consider and ask questions.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have approved this paper for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"147"}}